

WELCOME LETTER



Dear Colleagues and Friends,

It is with great pleasure that, following the great success reached during the previous three editions, I am pleased to welcome you at the 4th International Meeting on New Drugs in Breast Cancer.

More and more increasing knowledge on biology of breast cancer have produced great improvements in the treatment (cure, prolongation of survival, palliation of symptoms) based on the availability of novel targeted therapeutics.

Therefore the approach to the treatment cure of breast cancer represents a continuing challenge for physicians and patients. The Scientific Program of the next Meeting includes topics on Target Therapy, on Chemotherapy and on Hormonal therapy, but also new advances in supportive care, some lectures and video conferences on more general aspects as well as biology in localized disease, hormonal pathways, prognostic factors or specific items (immunology, biology of specific subtype etc).

The program has been designed in the pursuit of excellence and all lectures will be presented by an international distinguished outstanding faculty who will report all their experiences and developments.

I hope you will enjoy this program and I hope you can come for a unique and enjoyable stay in our beautiful city.

Francesco Cognetti

SCIENTIFIC COMMITTEE

E. Bria (Verona, I)
S. Cinieri (Brindisi, I)
P. Conte (Padua, I)
M. De Laurentiis (Naples, I)
S. De Placido (Naples, I)
L. Del Mastro (Genoa, I)
S. Gori (Verona, I)
P. Pronzato (Genoa, I)
F. Puglisi (Udine, I)

LOCAL SCIENTIFIC COORDINATORS

Alessandra Fabi
Cecilia Nisticò

LOCAL SCIENTIFIC COMMITTEE

Paolo Carlini
Paola Malaguti
Paola Papaldo

CONGRESS VENUE AND GENERAL INFORMATION

The Scientific Sessions will be held on November 12-13, 2015 at the Regina Elena National Cancer Institute - "Raffaele Bastianelli" Congress Centre (via Fermo Ognibene, 23 - 00144 Rome).

Language

The official language of the Congress is English. Simultaneous translation will not be provided.

Certificate of attendance

Certificates will be issued to all registered participants who will expressly make request at the Secretariat Desk at the end of the Congress.

CME Credits

The Congress will apply for CME Credits.

REGISTRATION INFORMATION

- | | |
|--|-----------------------------|
| · Registration Fee | € 183,00 (VAT 22% included) |
| · Registration for doctors of Regina Elena National Cancer Institute | FREE |
| · Post graduate students | FREE |

The registration fee entitles delegates to the following:

- entry to scientific sessions
- 1 coffee break and 1 buffet lunch on November 12 and 13, 2015
- CME credits
- congress material
- certificate of attendance

For further information or to register please visit the official website:

<http://web.aimgroupinternational.com/2015/breastcancer>

or write to: breastcancer2015@aimgroup.eu

PROVIDER E.C.M.

AIM Education

Via G. Ripamonti, 129 - 20141 Milan
Ph. +39 02 56601.1 - Fax +39 02 70048585
cme@aimgroup.eu - www.aimeducation.it

ORGANIZING SECRETARIAT

AIM Group International



Rome Office
Via Flaminia, 1068 - 00189 Rome
Ph. +39 06 33053.1 - Fax +39 06 33053249
breastcancer2015@aimgroup.eu
<http://web.aimgroupinternational.com/2015/breastcancer>

4th International Meeting on New Drugs in Breast Cancer

ROME, NOVEMBER 12 - 13, 2015

Regina Elena National Cancer Institute
Bastianelli Congress Centre

PRESIDENT: *Francesco Cognetti*





Presenting: F. Cognetti

09.15 Lecture

How did HER2 translation research evolved during the years? (E. Perez)

1ST SESSION

HER2 FAMILY INHIBITORS

Chairmen: S. Cinieri, P. Conte

09.45 HER2 Multitarget : is the maximum impact on the cure? (K. Gelmon)

10.05 Pertuzumab and T-DM1 association: future results in early disease (C. Hudis)

PI3K/MTOR INHIBITORS

10.25 The new PI3k inhibitors and endocrine therapy (A. Di Leo)

10.45 Everolimus in locally advanced disease: a new challenge (TBD)

11.05 Pharmacological blockade of the PI3K/mTOR pathway as an ErbB-independent mechanisms of Trastuzumab resistance: novel therapeutic approach (K. Gelmon)

11.25 Discussion

11.45 Coffee break

PARP INHIBITORS

Chairmen: F. Puglisi, V. Adamo, S. De Placido

12.00 Parp inhibitors in BRCA associated advanced disease: only in triple negative tumors? (P. Conte)

CELL CYCLE INHIBITORS

12.20 Targeting cycline dependent kinase: what's the future in the different subtypes? (M. Cristofanilli)

12.40 Endocrine therapy and CDK inhibitors: the state of the art (R.S. Finn)

ANGIOGENESIS INHIBITORS

13.00 Continuing VEGF blockade before disease progression: biological principles and clinical developments (G. Mustacchi)

13.20 Discussion

13.40 Lunch

2ND SESSION

IMMUNOTHERAPY

Chairmen: S. De Placido, S. Tomao, G. Tonini

14.30 Immunotherapy in clinical practice: how the pathologist can assist the clinicians? (G. Viale)

14.50 Immunotherapy and new immunology approaches in breast cancer and other solid tumors: the beginning of a dream? (G. Curigliano)

15.10 Discussion

FROM BIOLOGY TO THE CLINIC

Presenting: A. Di Leo

15.30 Lecture

The status of gene profiling and genomic landscape in treatment decision making (TBD)

15.50 Lecture

How and when should clinicians use gene signatures information? (C. Hudis)

Presenting: F. Montemurro

16.10 Lecture

Biomarkers of long-term benefit induced by HER2 inhibitors (M. Scaltriti)

16.40 Lecture

Inflammatory Breast Cancer: update of biological features (M. Cristofanilli)

17.10 Discussion



3RD SESSION

CYTOTOXIC DRUGS

Presenting: F. Cognetti

09.00 Lecture

Adjuvant treatment in Luminal B node negative tumors: various shades of gray (E. Perez)

Chairmen: A. Fabi, S. Gori

09.30 Eribulin: what is the right time to start treatment? (X. Pivot)

09.50 When the albumin bound paclitaxel improve standard treatment in large-operable/locally advanced disease: which is the next moving (G. von Minckwitz)

10.10 Discussion

10.30 Coffee break

SUPPORTIVE CARE IN BREAST CANCER

Chairmen: C. Ripamonti, E. Bria

10.45 Chemotherapy -induced neuropathy during and after adjuvant systemic treatment: the new developments for improving quality of life (C.L. Loprinzi)

11.05 Treating cancer related fatigue (C. Ripamonti)

11.25 Targeting bone metastatic cancer: the role of the new targets (D. Santini)

11.45 The new trends in treatment for the antiemetic prophylaxis (M. De Laurentiis)

12.05 The new long acting filgrastim for chemotherapy-induced neutropenia: which differences from the other molecules? (E. Bria)

12.25 Discussion

4TH SESSION

HORMONAL THERAPY

Presenting: G. Naso

12.45 Lecture

SERMS and AI as chemoprevention in risk individuals (TBD)

Chairmen: L. Del Mastro, G. Francini

13.15 Early breast cancer in premenopausal: are we ready to change clinical practice? (C. Tondini)

13.35 Androgens and breast cancer: what is coming? (P. Pronzato)

13.55 Discussion and Conclusions

14.10 Lunch